ReviewJournal of the renin-angiotensin-aldosterone system : JRAAS
The role of renin-angiotensin system in patients with left ventricular assist devices.
Review in Journal of the renin-angiotensin-aldosterone system : JRAAS. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Guideline directed-medical therapy for heart failure within 3 months post LVAD implant and rehospitalization.JHLT open · 2026Article
- Memory of the renin-angiotensin system following heart transplantation or implantation of a left ventricular assist device.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Pulse pressure as an early mortality predictor in neonates with congenital diaphragmatic hernia on veno-arterial ECMO.Pediatric surgery international · 2026Article
- Clinical Evaluation of Doppler Blood Pressure Measurement in Continuous-Flow LVAD Patients: Implications for Postoperative Management.Journal of cardiovascular development and disease · 2026Article
- Chronic kidney disease following left ventricular assist device implantation: contemporary insights and future perspectives.Heart failure reviews · 2025Review
- The Effect of Perioperative Fluid Therapy on Postoperative Renal Functions in Patients Receiving Liver Transplantation from Living Donors: A Retrospective Observational Study.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025Article
- Estimated glucose disposal rate mediates the association between Life's Crucial 9 and congestive heart failure: a population-based study.Frontiers in endocrinology · 2025Article
- Exosome-Mediated Angiogenesis Underlies LVAD-Induced Bleeding in Patients With End-Stage Heart Failure.JACC. Basic to translational science · 2022Article
- Changes in renin-angiotensin-aldosterone system during cardiac remodeling after mitral valvuloplasty in dogs.Journal of veterinary internal medicine · 2022Article
- Ventricular assist device-promoted recovery and technical aspects of explant.JTCVS techniques · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
End-stage heart failure is a condition in which the up-regulation of the systemic and local renin-angiotensin-aldosterone system (RAAS) leads to end-organ damage and is largely irreversible despite optimal medication. Left ventricular assist devices (LVADs) can downregulate RAAS activation by unloading the left ventricle and increasing the cardiac output translating into a better end-organ perfusion improving survival. However, the absence of pulsatility brought about by continuous-flow devices may variably trigger RAAS activation depending on left ventricular (LV) intrinsic contractility, the design and speed of the pump device. Moreover, the concept of myocardial recovery is being tested in clinical trials and in this setting LVAD support combined with intense RAAS inhibition can promote recovery and ensure maintenance of LV function after explantation. Blood pressure control on LVAD recipients is key to avoiding complications as gastrointestinal bleeding, pump thrombosis and stroke. Furthermore, emerging data highlight the role of RAAS antagonists as prevention of arteriovenous malformations that lead to gastrointestinal bleeds. Future studies should focus on the role of angiotensin receptor inhibitors in preventing myocardial fibrosis in patients with LVADs and examine in greater details the target blood pressure for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.